Chondroguard (sodium chondroitin sulfate) 100 mg/ml x 10 ampoules solution

  • $54.40
Sku: 19571de33cfc
Ingredient: Chondroitin Sulfate
The instruction for medical use

of Hondrogard Torgovoye medicine a name

Hondrogard

Mezhdunarodnoye the unlicensed name

Is not present

the Dosage form

Solution for intramuscular introduction of 100 mg/ml

Structure

1 ampoule contains

active agent: chondroitin sodium sulfate - 100 mg,

excipients: benzyl alcohol, sodium metabisulphite,

sodium hydroxide, water for injections.

The description

Transparent colourless or with slightly yellowish shade solution with a smell of benzyl alcohol

Pharmacotherapeutic group

Non-steroidal anti-inflammatory drugs others.

ATH M01AX25 code

Pharmacological action

Pharmacokinetics

After intramuscular administration of chondroitin sulfate is quickly distributed. In 30 min. after an injection it is found in blood in considerable concentration. The maximum concentration (Cmax) of chondroitin of sulfate in plasma is reached in 1 h, then gradually decreases within 2 days.

Chondroitin sulfate collects, mainly, in cartilaginous tissue of joints. The synovial membrane is not an obstacle for penetration of drug into a joint cavity. In experiments it is shown that in 15 min. after an intramuscular injection of chondroitin sulfate is found in synovial fluid, then gets into a joint cartilage where its Cmax is reached in 48 h. It is brought out of an organism within 24 hours. It Eliminirutsya mainly by kidneys.

A pharmacodynamics

Chondroitin sulfate - the high-molecular mucopolysaccharide influencing exchange processes in a hyaline cartilage. Reduces degenerative changes in cartilaginous tissue of joints, accelerates processes of its restoration, stimulates synthesis of proteoglycans, has hondroprotektivny, anti-inflammatory, analgeziruyushchy effect.

At drug treatment the morbidity decreases and the mobility of the affected joints improves. At treatment of degenerative changes

of joints with development of a secondary synovitis, the positive effect can

be observed in 2-3 weeks after the beginning of administration of drug the joint pain decreases, clinical manifestations of a reactive

synovitis disappear, the volume of movements in the affected joints increases.

The therapeutic effect remains a long time after the termination

of a course of treatment.

Indications

Degenerative dystrophic diseases of joints and backbone:

- an osteoarthrosis with primary damage of large joints

- intervertebral osteochondrosis

the Route of administration and doses

appoint Drug intramusculary on 100 mg every other day. At good tolerance the dose is increased to 200 mg, since the fourth injection.

A course of treatment - 25-30 injections. If necessary in 6 months carrying out a repeated course of treatment is possible.

Side effect

Allergic reactions (skin itching, an erythema, a small tortoiseshell, dermatitis),

hemorrhages in the place of an injection

of the Contraindication

- hypersensitivity to drug or to its components

- bleedings and tendency to bleeding

- thrombophlebitises

- pregnancy and the period of a lactation

- children's age up to 18 years

Medicinal interactions

At the combined use with non-steroidal anti-inflammatory drugs Hondrogard allows to lower a dose of non-steroidal anti-inflammatory drugs. Drug strengthens effect of indirect anticoagulants, antiagregant, fibrinolitik that demands more frequent control of indicators of fibrillation at combined use.

Special instructions

achievement of stable clinical effect requires not less than 25 injections of Hondrogard. For prevention of aggravations repeated courses of treatment are shown.

Use in pediatrics

the Data on efficiency and safety of use of chondroitin of sulfate for children are absent now.

Features of influence of medicine on ability to run

the vehicle or potentially dangerous mechanisms

the Overdose does not influence

Now about cases of overdose of chondroitin of sulfate

it was not reported.

A form of release and packing

Solution for intramuscular introduction of 100 mg/ml.

On 1 ml in ampoules of colourless neutral glass with a color ring

of a break or with a color point and a notch and/or with additional

color identification rings or other coding.

On 5 ampoules in blister strip packaging from a film of polyvinylchloride

and aluminum foil, or a film polymeric, or without foil and a film.

On the 2nd blister strip packagings together with the instruction for medical

use in the state and Russian languages in a pack from cardboard.

To Store storage conditions in the place protected from light at a temperature not over 25C.

To store out of children's reach!

2 years

not to use a period of storage after an expiration date.
Write a review
Related Products
KorolevPharm (Russia)
Comfrey Sustavit Sabelnikov with 125 ml of gel for body balm
$4.60
WORLD MEDICINE (Turkey)
Muskomed 0.25% 30g cream
$26.30
KorolevPharm (Russia)
Zhivokost 75 ml warming balsam
$7.30
VIS (Russia)
Fulfleks (24 capsules)
$19.80
BORIMED (Belarus)
Indomethacin 10% 40g ointment tube
$2.90
Out Of Stock
Heel (Germany)
The purpose (50 tablets)
$23.50
F. Hoffmann-La Roche Ltd. (Switzerland)
1's Bonviva 150 mg coated tablets
$115.80
Out Of Stock